JNJ vs V: Which Is the Better Buy?

Side-by-side comparison of Johnson & Johnson and Visa Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-25.
Johnson & Johnson Β· Healthcare
$270.68
+5.7% upside to fair value
Med Conviction Grade C High Quality
VS
Visa Inc. Β· Financial Services
$368.29
+25.7% upside to fair value
Med Conviction Grade B High Quality
QuantHub Verdict
V has more upside to fair value (+25.7%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric JNJ V
Current Price $270.68 $368.29
Fair Value Estimate $286.05 $463.00
Upside to Fair Value +5.7% +25.7%
Market Cap $652.3B $687.6B
Forward P/E β€” β€”
EV / EBITDA 20.2x 24.0x
Price / Sales 6.7x 15.5x
Price / FCF 35.3x 33.5x
Revenue Growth YoY +6.6% +14.4%
Gross Margin 67.9% 80.2%
Operating Margin 26.8% 60.7%
Return on Equity 25.7% 61.3%
Dividend Yield 1.95% 0.73%
FCF Yield 2.83% 2.98%
Analyst Consensus Buy Strong Buy
Investment Thesis
JNJ β€” Johnson & Johnson
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
V β€” Visa Inc.
Visa operates the world's largest retail payments network, connecting consumers, merchants, issuers, and acquirers through VisaNet, which authorizes, clears, and settles transactions across more than 200 countries. The business quality is exceptional: TTM gross margin of 80.2%, operating margin of 60.7%, net margin of 50.8%, and ROE of 61.3% reflect a two-sided network with powerful scale economi…
Accumulation Zones
Metric JNJ V
Zone Low $214.54 $347.25
Zone High $243.14 $393.55
In Buy Zone? No Yes
← JNJ Research    V Research β†’    All Research